Drug

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA
ADC / XDCKelun Pharmaceutical

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that a new indication application for sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) has been accepted for review by the Center for…

Joincare's LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Joincare’s LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Hengrui's Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Hengrui’s Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Jemincare's Irinotecan Liposome Injection Gains NMPA Approval for Pancreatic Cancer
CancerJemincare

Jemincare’s Irinotecan Liposome Injection Gains NMPA Approval for Pancreatic Cancer

Novo Nordisk's Wegovy Demonstrates Early Cardioprotective Effects in SELECT Trial
Clinical trial resultsCPH: NOVO-B

Novo Nordisk’s Wegovy Demonstrates Early Cardioprotective Effects in SELECT Trial

GSK's Blenrep Recommended for EU Approval in Multiple Myeloma
ADC / XDCCancer

GSK’s Blenrep Recommended for EU Approval in Multiple Myeloma

Dizal Pharma Presents DZD8586 and DZD6008 Results at ASCO 2025
Clinical trial resultsDizal Pharmaceutical

Dizal Pharma Presents DZD8586 and DZD6008 Results at ASCO 2025

Show More